Approximately 25-27 million Americans have asthma, and severe asthma affects an estimated 5-10% of that population, roughly 1.2-2.7 million individuals, yet it remains systematically under documented in primary care. Many patients meeting criteria for severe persistent disease carry a generic asthma diagnosis that does not reflect their true symptom burden, exacerbation frequency, or treatment intensity. Severe asthma patients generate an estimated $12,000-$25,000 or more in annual costs compared to $3,000-$5,000 for mild-to-moderate disease, underscoring the clinical and care coordination stakes of accurate severity documentation.
AAVBC's Severe Asthma Quick Reference Guide equips primary care clinicians and care teams with a comprehensive, evidence-aligned reference covering ICD-10 severity coding specificity, spirometry and bronchodilator reversibility thresholds, biologic therapy eligibility criteria, stepwise treatment escalation, oral corticosteroid dependence documentation, exacerbation history requirements, comorbidity screening, and MEAT documentation standards. Grounded in current GINA and NAEPP guideline evidence, this guide supports consistent, individualized clinical decision-making, helping care teams build complete clinical pictures that reflect true disease burden, with the documentation precision and continuity that durable outcomes.
AAVBC’s Deep-Dive series offers a comprehensive, structured analysis of severe asthma — moving far beyond quick-reference essentials. These guides provide an integrated review of epidemiology, diagnostic strategy, staging, coding logic, MEAT-aligned documentation examples, treatment guidelines, review vulnerabilities, and cost-utilization considerations. The Deep-Dive combines evidence-informed clinical guidance with practical operational tools to support a deeper understanding of disease complexity and provide multidisciplinary teams with strategies to thrive within value-based frameworks.
Approximately 25-27 million Americans have asthma, and severe asthma affects an estimated 5-10% of that population, roughly 1.2-2.7 million individuals, yet it remains systematically under documented in primary care. Many patients meeting criteria for severe persistent disease carry a generic asthma diagnosis that does not reflect their true symptom burden, exacerbation frequency, or treatment intensity. Severe asthma patients generate an estimated $12,000-$25,000 or more in annual costs compared to $3,000-$5,000 for mild-to-moderate disease, underscoring the clinical and care coordination stakes of accurate severity documentation.
AAVBC's Severe Asthma Quick Reference Guide equips primary care clinicians and care teams with a comprehensive, evidence-aligned reference covering ICD-10 severity coding specificity, spirometry and bronchodilator reversibility thresholds, biologic therapy eligibility criteria, stepwise treatment escalation, oral corticosteroid dependence documentation, exacerbation history requirements, comorbidity screening, and MEAT documentation standards. Grounded in current GINA and NAEPP guideline evidence, this guide supports consistent, individualized clinical decision-making, helping care teams build complete clinical pictures that reflect true disease burden, with the documentation precision and continuity that durable outcomes.
AAVBC’s Deep-Dive series offers a comprehensive, structured analysis of severe asthma — moving far beyond quick-reference essentials. These guides provide an integrated review of epidemiology, diagnostic strategy, staging, coding logic, MEAT-aligned documentation examples, treatment guidelines, review vulnerabilities, and cost-utilization considerations. The Deep-Dive combines evidence-informed clinical guidance with practical operational tools to support a deeper understanding of disease complexity and provide multidisciplinary teams with strategies to thrive within value-based frameworks.
